Skip to main content
Premium Trial:

Request an Annual Quote

SAIC-Frederick to Use ABI s TaqMan Collection to Genotype Cancer Samples

NEW YORK, April 4 (GenomeWeb News) - The Core Genotyping Facility of SAIC-Frederick, a contractor for the National Cancer Institute, will use Applied Biosystems' genotyping assays to study genetic variations in a number of cancer samples, the two organizations said today.

 

SAIC-Frederick will use more than 2,400 of ABI's TaqMan drug metabolism genotyping assays to genotype samples from the International HapMap project and from NCI's SNP500Cancer standard sample panel. In addition, it will use a number of assays to genotype individuals from a study evaluating treatment for Non-Hodgkin's lymphoma.

 

ABI and the Core Genotyping Facility will jointly analyze the resulting genotyping data and plan to post their findings on the SNP500Cancer website and publish further findings. The aim of the study is to better understand genetic differences associated with responses to cancer treatment.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.